269 related articles for article (PubMed ID: 24147368)
1. Evaluation and enhancement of physical stability of semi-solid dispersions containing piroxicam into hard gelatin capsules.
Karataş A; Bekmezci S
Acta Pol Pharm; 2013; 70(5):883-97. PubMed ID: 24147368
[TBL] [Abstract][Full Text] [Related]
2. Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol.
Karataş A; Yüksel N; Baykara T
Farmaco; 2005 Sep; 60(9):777-82. PubMed ID: 16084514
[TBL] [Abstract][Full Text] [Related]
3. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
4. Preparation and evaluation of solid dispersions of piroxicam and Eudragit S100 by spherical crystallization technique.
Maghsoodi M; Sadeghpoor F
Drug Dev Ind Pharm; 2010 Aug; 36(8):917-25. PubMed ID: 20180658
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro characterization of a semi-solid dispersion of flurbiprofen with Gelucire 44/14 and Labrasol.
Soliman MS; Khan MA
Pharmazie; 2005 Apr; 60(4):288-93. PubMed ID: 15881610
[TBL] [Abstract][Full Text] [Related]
6. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
Zahedi P; Lee PI
Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
[TBL] [Abstract][Full Text] [Related]
7. Studies on aging piroxicam-polyvinylpyrrolidone solid dispersions.
Ingkatawornwong S; Kaewnopparat N; Tantishaiyakul V
Pharmazie; 2001 Mar; 56(3):227-30. PubMed ID: 11265589
[TBL] [Abstract][Full Text] [Related]
8. Dissolution, bioavailability and ulcerogenic studies on piroxicam-nicotinamide solid dispersion formulations.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2003 Apr; 142(3):119-24. PubMed ID: 12806831
[TBL] [Abstract][Full Text] [Related]
9. Amorphous solid dispersions of piroxicam and Soluplus(®): Qualitative and quantitative analysis of piroxicam recrystallization during storage.
Lust A; Strachan CJ; Veski P; Aaltonen J; Heinämäki J; Yliruusi J; Kogermann K
Int J Pharm; 2015; 486(1-2):306-14. PubMed ID: 25843761
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems.
Pan RN; Chen JH; Chen RR
Drug Dev Ind Pharm; 2000 Sep; 26(9):989-94. PubMed ID: 10914324
[TBL] [Abstract][Full Text] [Related]
11. Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate.
Ambrogi V; Perioli L; Marmottini F; Giovagnoli S; Esposito M; Rossi C
Eur J Pharm Sci; 2007 Nov; 32(3):216-22. PubMed ID: 17826966
[TBL] [Abstract][Full Text] [Related]
12. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
[TBL] [Abstract][Full Text] [Related]
13. Fast dissolving cyclodextrin complex of piroxicam in solid dispersion part I: influence of β-CD and HPβ-CD on the dissolution rate of piroxicam.
Bouchal F; Skiba M; Chaffai N; Hallouard F; Fatmi S; Lahiani-Skiba M
Int J Pharm; 2015 Jan; 478(2):625-32. PubMed ID: 25522828
[TBL] [Abstract][Full Text] [Related]
14. The dissolution enhancement of piroxicam in its physical mixtures and solid dispersion formulations using gluconolactone and glucosamine hydrochloride as potential carriers.
Al-Hamidi H; Obeidat WM; Nokhodchi A
Pharm Dev Technol; 2015 Jan; 20(1):74-83. PubMed ID: 24392858
[TBL] [Abstract][Full Text] [Related]
15. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone.
Tantishaiyakul V; Kaewnopparat N; Ingkatawornwong S
Int J Pharm; 1999 Apr; 181(2):143-51. PubMed ID: 10370210
[TBL] [Abstract][Full Text] [Related]
16. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method.
Zajc N; Obreza A; Bele M; Srcic S
Int J Pharm; 2005 Mar; 291(1-2):51-8. PubMed ID: 15707731
[TBL] [Abstract][Full Text] [Related]
17. Characterization and stability of solid dispersions based on PEG/polymer blends.
Bley H; Fussnegger B; Bodmeier R
Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the in-vitro dissolution and in-vivo oral bioavailability of silymarin from liquid-filled hard gelatin capsules of semisolid dispersion using Gelucire 44/14 as a carrier.
Hussein A; El-Menshawe S; Afouna M
Pharmazie; 2012 Mar; 67(3):209-14. PubMed ID: 22530301
[TBL] [Abstract][Full Text] [Related]
19. Rheology and filling characteristics of particulate dispersions in polymer melt formulations for liquid fill hard gelatin capsules.
Rowley G; Hawley AR; Dobson CL; Chatham S
Drug Dev Ind Pharm; 1998 Jul; 24(7):605-11. PubMed ID: 9876504
[TBL] [Abstract][Full Text] [Related]
20. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
